• Ann Tucker

FDA Approves Higher Dosage of Naloxone

The Food and Drug Administration recently announced the approval of a higher dose of naloxone nasal spray to treat opioid overdose. The FDA previously approved 2 mg and 4 mg naloxone products and has now approved the delivery of 8 mg of naloxone. As described in the press release, the approval of 8 mg naloxone is another step the agency has taken to improve the availability of naloxone products. The agency has also encouraged manufacturers to pursue approval of over-the-counter naloxone products; required drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to prescribing information; and has extended the shelf life of naloxone from 24 months to 36 months. Read more

4 views0 comments

Recent Posts

See All

HHS Releases Strategic Plan for Health Workforce

HHS recently released its Health Workforce Strategic Plan, as mandated by the CARES Act. In the plan, HHS prioritizes: recruiting and training health professionals from underserved communities; ensuri

CLASPPlogonoline-01.png